Is Amivantamab available in China?

Amivantamab (Amivantamab) is a new targeted antibody drug used to treat certain patients with non-small cell lung cancer (NSCLC). It is designed to fight EGFR (epidermal growth factor receptor) mutant NSCLC, a subtype of lung cancer. EGFRMutatedNSCLCare often resistant to traditional treatments, but evantumumab provides a new treatment option for this patient population.

Evantumumab is not yet available in China, so patients cannot purchase it domestically and need to purchase it through foreign channels. There are only European versions of original drugs available abroad, and the price is relatively high, around 20,000 yuan.

Evantumumab is unique in that it has a dual mechanism designed to attack EGFRmutations and METamplifications, both of which are very common in EGFRpositive lung cancers. This antibody drug improves the effectiveness of treatment by blocking these signaling pathways and inhibiting the growth and spread of tumor cells.

Results of evantumumab showed that it achieved significant efficacy in EGFRmutatedNSCLC patients, including those who had received other treatments but developed drug resistance. This provides a new treatment hope for EGFRmutatedNSCLC patients, which can extend their survival and improve their quality of life.

As a targeted antibody drug, evantumumab is usually given to patients via intravenous injection, and the treatment cycle varies depending on individual circumstances. However, its use may be associated with some side effects, including skin rash, nausea, fatigue, etc., so doctors need to carefully monitor the patient's response and provide supportive care.